Experimental therapies in Ewing's sarcoma

Expert Opinion on Investigational Drugs

Volumn 18, Issue 2, 2009, Pages 143-159

  Windsor, Rachael ^a   Strauss, Sandra ^a   Seddon, Beatrice ^a   Whelan, Jeremy ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Biological therapies; Cytotoxics; Ewing's sarcoma PNET; Experimental therapies

Indexed keywords

ADW 742; AMG 479; ANTHRACYCLINE; BISPHOSPHONIC ACID DERIVATIVE; BUSULFAN; CAMPTOTHECIN; CANCER VACCINE; CD99 ANTIBODY; CP 751 871; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FENRETINIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IMC A 12; IRINOTECAN; L9 NC; LYMPHOCYTE ANTIBODY; MELPHALAN; MONOCLONAL ANTIBODY; OSI 906; R 1507; RAPAMYCIN; SCH 717 454; TEMOZOLOMIDE; TOPOTECAN; TRABECTEDIN; TREOSULFAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT;

BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER RISK; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG CARCINOGENICITY; DRUG CYTOTOXICITY; DRUG FATALITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; EWING SARCOMA; FATIGUE; HIGH RISK PATIENT; HUMAN; INTERSTITIAL PNEUMONIA; LEIOMYOSARCOMA; LUNG NON SMALL CELL CANCER; MELANOMA; MOLECULAR DYNAMICS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; NEUROECTODERM TUMOR; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; OVARY TUMOR; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PERIPHERAL EDEMA; QUALITY OF LIFE; REVIEW; RHABDOMYOSARCOMA; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SOFT TISSUE SARCOMA; TARGET CELL; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WHOLE BODY RADIATION; ANIMAL; BONE TUMOR; IMMUNOTHERAPY; PATHOLOGY; PHASE 3 CLINICAL TRIAL;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; IMMUNOTHERAPY; SARCOMA, EWING'S;

EID: 65549086994     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780802715784     Document Type: Review

References (128)

1. Ewing J. Diffuse endothelioma of bone. Proc NY Pathol Soc 1921;21:17-22 •• Description of a new disease together with discussion of defining clinical characteristics.
2. World Health Organisation International Classification of Diseases. Available from: http://www.who.int/classifications/apps/icd/icd10online/ [Last accessed 19 December 2008]
3. Stiller CA, Bielack SS, Jundt G, Steliarova-Foucher E. Bone tumours in European children and adolescents 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006;42:2124-2135
4. Widhe B, Widhe T. Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma. J Bone Joint Surg Am 2000;82:667-674 (Pubitemid 30307868)
5. Paulussen M, Ahrens S, Dunst J, et al. Localized Ewing tumor of bone: Final results of the Cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol 2001;19:1818-1829 (Pubitemid 32230885)
6. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000;18:3108-3114 • Multivariate analysis of prognostic factors in a large international cohort. (Pubitemid 30677091)
7. Bernstein M, Kovar H, Paulussen M, et al. Ewing's Sarcoma Family of Tumors: Current Management. Oncologist 2006;11:503-519 (Pubitemid 43788277)
8. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992;359:162-165
9. Riggi R, Stamenkovic I. The Biology of Ewing sarcoma. Cancer Lett 2007;254:1-10 • Excellent review on the biology of ES/PNET. (Pubitemid 47058800)
10. Ludwig JA. Ewing sarcoma: historical perspectives, current state-of-the-art and opportunities for targeted therapy in the future. Curr Opin Oncol 2008;20:412-418
11. Delattre O, Zucman J, Melot T, et al. The Ewing family of tumors - a subgroup of small-round-cell tumors defined by specific shimeric transcripts. N Engl J Med 1994;331(5):294-299 •• Defining description of early translational research into ES/PNET. (Pubitemid 24236016)
12. Patricio MB, Vilhena M, Neves M, et al. Ewing's sarcoma in children: twenty five years of experience at the Instituto Portuges de Oncologica de Francisco Gentil (I.P.O.F.G). J Surg Oncol 1991;47:37-40
13. Stiller CA, Craft AW, Corozziari I; and the EUROCARE Working Group. Survival of children with bone sarcoma in Europe since 1978: results from the EUROCARE study. Eur J Cancer 2001;37:760-766
14. Castex MP, Rubie H, Stevens M, et al. Extraosseous Localized Ewing Tumors: Improved Outcome with Anthracyclines-The French Society of Pediatric Oncology and International Society of Pediatric Oncology. J Clin Oncol 2007;25:1176-1182 (Pubitemid 46640563)
15. Paulussen M, Craft AW, Lewis I, et al. Results of the EICESS-92 Study: Two Randomized Trials of Ewing's Sarcoma Treatment - Cyclophosphamide Compared with Ifosfamide in Standard-Risk Patients and Assessment of Benefit of Etoposide Added to Standard Treatment in High-Risk Patients. J Clin Oncol 2008;26(27):4385-4393 •• Results of two large randomised international studies addressing novel clinical questions.
16. Iwamoto Y. Diagnosis and Treatment of Ewing's Sarcoma. Jpn J Clin Oncol 2007;37(2):79-89 (Pubitemid 47090704)
17. Sutow WW, Sullivan MP. Cyclophosphamide therapy in children with Ewing's sarcoma. Cancer Chemother Rep 1962;23:55-60
18. Pinkel D. Cyclophosphamide in children with cancer. Cancer 1962;15:42-49
19. Nesbit ME, Gehan EA, Burgert EO Jr, et al. Multimodal therapy for the management of primary, non-metastatic Ewing's sarcoma of bone: a long term follow up of the first Intergroup study. J Clin Oncol 1990;8:1664-1674 (Pubitemid 20334321)
20. Burgert EO Jr, Nesbit ME, Garnsey LA, et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: Intergroup study of IESS II. J Clin Oncol 1990;8:1514-1524 (Pubitemid 20301182)
21. Craft A, Cotterill S, Malcol A, et al. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumour Study. J Clin Oncol 1998;16:3628-3633 • Important data on the addition of ifosfamide. (Pubitemid 28506777)
22. Miser KS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 1987;5:1191-1198 (Pubitemid 18045304)
23. Kung FH, Pratt CB, Vega RA, et al. Ifosfamide/etoposide combination in the treatment of recurrent soild tumors of childhood: a Pediatric Oncology Group Phase II Study. Cancer 1993;71:1898-1903 (Pubitemid 23067411)
24. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumour of bone. N Engl J Med 2003;348:694-701 (Pubitemid 36237038)
25. EURO-E.W.I.N.G. Study Committee. EURO-E.W.I.N.G. 99 Study Manual-EUROpean Ewing tumour Working Initiative of National Groups Ewing Tumour Studies 1999. Protocol Version 2 Aug 2005
26. Bacci G, Forni C, Longhi A, et al. Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer 2004;40:73-83 (Pubitemid 37542320)
27. Strauss SJ, McTiernan A, Driver D, et al. Single centre experience of a new intensive induction therapy for ewing's family of tumors: feasibility, toxicity, and stem cell mobilization properties. J Clin Oncol 2003;21(15):2947-2981 (Pubitemid 46621850)
28. Miser JS, Goldsby R, Chen S, et al. Treatment of metastatic Ewing Sarcoma/Primitive Neuroectodermal Tumor of Bone: Evaluation of Increasing the Dose Intensity of Chemotherapy - A Report From the Children's Oncology Group. Pediatr Blood Cancer 2007;49:894-900 (Pubitemid 350022441)
29. Womer RB, West DC, Krailo MD, et al. for the Children's Oncology Group AEWS0031 Committee. Randomized comparison of every-two-week v every-three-week chemotherapy in Ewing Sarcoma Family Tumours (ESFT) [abstract 10504]. JCO 2008;26(Suppl)
30. Morales-Arias J, Meyers P, Bolontrade M, et al. Expression of Granulocyte-Colony-Stimulating Factor and its Receptor in Human Ewing Sarcoma Cells and Patient Tumor Specimens. Potential Consequences of Granulocyte-Colony-Stimulating Factor Administration. Cancer 2007;110:1568-1577
31. Rodriguez-Galindo C, Billups CA, Kun LE, et al. Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979-1999. Cancer 2002;94:561-569
32. Shankar AG, Ashley AS, Craft AW, Pinkerton CR. Outcome after relapse in an unselected cohort of children and adolescents with Ewing's sarcoma. Med Pediatr Oncol 2003;40:141-147 (Pubitemid 36110274)
33. Barker LM, Pendergrass TM, Sanders JE, Hawkins DS. Survival after recurrence of Ewing's Sarcoma Family of Tumors. J Clin Oncol 2005;23:4353-4362 (Pubitemid 46207009)
34. McTiernan M, Cassoni A, Driver D, et al. Improving Outcomes After Relapse in Ewing's Sarcoma: Analysis of 114 Patients From a Single Institution. Sarcoma 2006 ; Article ID 83548:1-8 • Largest reported cohort of outcome of uniformly treated relapsed patients. (Pubitemid 44826828)
35. Cornbleet MA, Corringham R, Prentice H. Treatment of Ewing's sarcoma with high-dose melphalan and autologous bone marrow transplantation. Cancer Treat Rep 1981;65:241-244 (Pubitemid 11071432)
36. Graham-Pole J, Lazarus HM, Herzig R, et al. High dose melphalan therapy for the treatment of children with refractory neuroblastoma and Ewing's sarcoma. Am J Pediatr Hematol Oncol 1984;6(1):17-26 (Pubitemid 14128395)
37. Hartmann O, Benhamou E, Beaujean F, et al. High dose melphalan and cyclophosphamide with autologous bone marrow transplantation support in advanced malignancies in children: A Phase II study. J Clin Oncol 1986;4:1804-1810 (Pubitemid 17226671)
38. Burdach S, van Kaick B, Laws HJ, et al. Allogeneic and autologous stem cell transplantation in advanced Ewing tumors. An update after long term follow up from two centers of the European Intergroup study EICESS.Stem-Cell Transplant Programs at Dusseldorf University Medical Center, Germany and St Anna Kinderspital, Vienne, Austria. Ann Oncol 2000;11:1451-1462
39. Drabko K, Zawitkowska-Klaczynska J, Wojcik B, et al. Megachemotherapy followed by autologous stem cell transplantation in children with Ewing's Sarcoma. Pediatr Transplant 2005;9:618-621 (Pubitemid 41413501)
40. Oberlin O, Rey A, Desfachelles A, et al. Impact of High -Dose Busulphan plus Melphalan as Consolidation in metastatic Ewing Tumors: A Study by the Societe Francaise des Cancers de l'Enfant. J Clin Oncol 2006;24(24):3997-4002 (Pubitemid 46630750)
41. McTiernan A, Driver D, Michelagnoli M, et al. High dose chemotherapy with peripheral stem cell rescue or bone marrow is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumours. Ann Oncol 2006;17:1301-1305 (Pubitemid 44288222)
42. Al-Faris N, Al Harbi T, Goia C, et al. Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing Sarcoma? Pediatr Blood Cancer 2007;49:190-195
43. Ladenstein R, Lasset C, Pinkerton R, et al. Impact of megatherapy in children with high risk Ewing's tumours in complete remssion: a report from the EBMT Solid Tumour Registry. Bone Marrow Transplant 1995;15:697-705
44. Seddon B, Cassoni AM, Galloway MJ, et al. Fatal radiation myelopathy after high-dose busulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice. Clin Oncol (R Coll Radiol) 2006;18(1):86
45. Werner S, Mendoza A, Hilger R, et al. Preclinical studies of treosulfan demonstrate potent activity in Ewing's Sarcoma. Cancer Chemother Pharmacol 2008;62:19-31
46. Wachowiak J, Chybicka A, Kowalczyk J, et al. Retrospective study on treosulfan-based preparative regimen for allogeneic HSCT in children with haematological malignancies and high risk of conventional regimen related toxicity [abstract]. Bone Marrow Transplant 2005;35(S2):261
47. Pappo A, Lyden E, Breneman J, et al. Up-Front window trial of Topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: An Intergroup Rhabdomyosarcoma Study. J Clin Oncol 2001;19:213-219 (Pubitemid 32063499)
48. Bernstein B, Devidas M, Lafreniere D, et al. Intensive therapy with growth factor support in patients with Ewing Tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Oncology Group Phase II study 9457 - A report from the Children's Oncology Group. J Clin Oncol 2006;24:152-159 (Pubitemid 46630507)
49. Saylors III R, Stine K, Sullivan J, et al. for the Pediatric Oncology Group. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumours: A Pediatric Oncology Group Phase II Study. J Clin Oncol 2001;19:3463-3469 (Pubitemid 32730082)
50. Saylors RL, Stewart C, Wall DA, et al. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumours: A Pediatric Oncology Group study. J Clin Oncol 1998;16:945-952 (Pubitemid 28108727)
51. Hunold A, Weddeling N, Paulussen M, et al. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer 2006;47:795-800 (Pubitemid 44476756)
52. National Cancer Institute, US National Institutes of Health. Phase III randomised study of doxorubicin hydrochloride, cyclophosphamide, vincristine, etoposide and ifosfamide with versus without topotecan hydrochloride in patients with newly diagnosed localized ewing's sarcoma. Available from: URL: http://www.cancer.gov/clinical trials/COG-AEWS0531 [Last accessed 12 November 2008]
53. Vassal G, Terrier-Lacombe MJ, Bissery MC, et al. Therapeutic activity of CPT-11, a DNA-toposomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Br J Cancer 1996;74:537-545 (Pubitemid 26279047)
54. 6-Methylguanine-DNA Methyltransferase and mismatch repair phenotypes in mouse models. Clin Cancer Res 2000;6:4110-4118
55. 6-methylguanine. Cancer Res 2001;61:53-58
56. Wagner LM, Crews KR, Iacono LC, et al. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res 2004;10:840-848 (Pubitemid 38198882)
57. Wagner LM, McAllister N, Goldsby R, et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing Sarcoma. Pediatr Blood Cancer 2007;48:132-139 (Pubitemid 44958268)
58. Aerosol L9-NC and Temozolomide in Ewing's Sarcoma (2005-0889). National Cancer Institute, US National Institutes of Health. Available from: URL: http://www.cancer.gov/clinical trials [Last accessed November 12th 2008]
59. Svancarova L, Blay JY, Hudson IR, et al. Gemcitabine in advanced adult soft-tissue sarcomas: A Phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002;38:556-559 (Pubitemid 34185396)
60. Verweij J, Catimel G, Sulkes A, et al. Phase II studies of docetaxel in the treatment of various solid tumours: EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1995;31A:S21-4
61. Meyer T, McTiernan A, Whelan J. A Phase II Study of Docetaxel in Relapsed and Refractory Ewing's Tumours. Sarcoma 2003;7(1):13-17 (Pubitemid 36577842)
62. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a Phase II trial. J Clin Oncol 2002;20:2824-2831 (Pubitemid 34651511)
63. Navid F, Willert J, McCarville MB, et al. Combination of Gemcitabine and Docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 2008;113:419-425
64. Maki RG, Wathen K, Patel SR, et al. Randomized Phase II Study of Gemcitabine and Docetaxel compared with Gemcitabine alone in patients with metastatic soft tissue sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002. J Clin Oncol 2007;25:2755-2763
65. Leu KM, Ostruszka LJ, Schewach D, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 2004;22:1706-1712 (Pubitemid 41079810)
66. SARC (Sarcoma Alliance for Research through Collaboration) Study 003: Phase II study of Sequential Gemcitabine Followed by Docetaxel for Recurrent Ewing's Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma. Available from: http://www.sarctrials.org/public/pag55.aspx [Last accessed 12 November 2008]
67. Lau L, Supko JG, Blaney S, et al. for the Children's Oncology Group. A Phase I and pharmacokinetic study of Ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group Study. Clin Cancer Res 2005;11:672-677
68. Hendriks HR, Fiebig HH, Giavazzi R, et al. High antitumour activity of ET-743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann Oncol 1999;10(10):1233-1240 (Pubitemid 29533575)
69. Li WW, Takahashi N, Jhanwar S, et al. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: Identification of Ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res 2001;7:2908-2911 (Pubitemid 32911401)
70. Scotlandi K, Perdichizzi S, Manara MC, et al. Effectiveness of Ecteinascidin-743 against Drug-sensitive and resistant Bone Tumour Cells. Clin Cancer Res 2002;8:3893-3903 (Pubitemid 35428818)
71. Lau L, Supko JG, Blaney S, et al. for the Children's Oncology Group. A Phase I and pharmacokinetic study of Ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group Study. Clin Cancer Res 2005;11:672-677
72. Roylance R, Seddon B, McTiernan A. Experience of the Use of Trabectedin (ET-743, Yondelis) in 21 Patients with Pre-treated Advance Sarcoma from a Single Centre. Clin Oncol 2007;19:572-576 (Pubitemid 47308646)
73. Phase I Study of Trabectedin in Pediatric Patients With Relapsed or Refractory Solid Tumors (NCI-07-C-0054) National Cancer Institute, US National Institutes of Health. Available from: URL: http://www.cancer.gov/clinicaltrials [Last accessed 12 November 2008]
74. COG-ADVL0221: A Phase II Study of Trabectedin (ET-743, Yondelis ®) in Children with Recurrent Rhabdomyosarcoma, Ewing Sarcoma, or Non-rhabdomyosarcomatous Soft Tissue Sarcomas. Available from: URL: http://www.cancer.gov/search/ViewClinicalTrials [Last accessed 19 December 2008]
75. Baserga R, Porcu P, Rubini M, Sell C. Cell cycle control by the IGF-I receptor and its ligands. Adv Exp Med Biol 1993;343:105-112 (Pubitemid 24059281)
76. Ryan PD, Goss PE. The emerging role of the Insulin-Like Growth Factor pathway as a therapeutic target in cancer. Oncologist 2008;13:16-24 (Pubitemid 351206693)
77. Sachdev D, Yee D. Disrupting insulin-like growth factor signalling as a potential cancer therapy. Mol Cancer Ther 2007;6(1):1-12 • Excellent review of the role of IGF-R in cancer. (Pubitemid 46206663)
78. Manara MC, Landuzzi L, Nanni P, et al. Preclinical in vivo study of new Insulin-Like Growth Factor-I Receptor-Specific inhibitor in Ewing's Sarcoma. Clin Cancer Res 2007;13(4):1322-1330 (Pubitemid 46424074)
79. Toretsky J, Kalebic T, Blakesley V, et al. The insulin-like growth factor receptor-1 is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997;272:30822-30827 (Pubitemid 27527522)
80. Scotlandi K, Benini S, Sarti M, et al. Insulin-like I Growth Factor receptor-mediated circuit in Ewing's Sarcoma/Peripheral Neuroectodermal Tumour: A possible therapeutic target. Cancer Res 1996;56:4570-4574 (Pubitemid 26338048)
81. Scotlandi K, Benini S, Nanni P, et al. Blockage of Insulin-like Growth Factor-I Receptor inhibits the growth of Ewing's Sarcoma in athymic mice. Cancer Res 1998;58:4127-4131 (Pubitemid 28440569)
82. SARC Global Collaboration (Sarcoma Alliance for Research through Collaboration): A Phase II Multi-Arm Trial of R1507 IGF1R, a Recombinant Human Monoclonal Antibody for the treatment of patients with recurrent or refractory Ewing's sarcoma, and other Soft Tissue Sarcomas. Available from: http://www.sarctrials.org/public/pag55.aspx [Last accessed 12 November 2008]
83. Martins A, Mackintosh C, Martin D, et al. Insulin Like Growth Factor Pathway Inhibition by ADW742, Alone or in Combination with Imatinib, Doxrubicin or Vincristine, is a Novel Therapeutic Approach in Ewing Tumor. Clin Cancer Res 2006;12(11):3532-3540 (Pubitemid 43910901)
84. Martins A, Ordonez J, Garcia-Sanchez A, et al. A Pivotal Role for Heat Shock Protein 90 in Ewing Sarcoma Resistance to Anti-Insulin-like Growth Factor 1 Receptor Treatment: In vitro and in vivo Study. Cancer Res 2008;68(15):6260-6270
85. Mateo-lozano S, Tirado OM, Notario V. Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation. Oncogene 2003;22(58):9282-9287 (Pubitemid 38122040)
86. Chawla SP, Tolcher AW, Staddon AP, et al. Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: update of phase II trial [abstract]. Proc Am Soc Clin Oncol 2007;25:3002-10076
87. Deforolimus (AP23573) in Treatment of Sarcoma - SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Deforolimus) Study (AP23573-07-302). Available from: http://www.cancer.gov/clinicaltrials/search [Last accessed 12 November 2008]
88. O'Reilly K, Rojo F, She Q, et al. mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signalling and Activates Akt. Cancer Res 2006;66(3):1500-1508 (Pubitemid 43259931)
89. Keedwell RG, Zhao Y, Hammond LA, et al. A Retinoid-related molecule that does not bind to classical retinoid receptors potently induces apoptosis in human prostate cancer cells through rapid caspase activation. Cancer Res 2004;64:3302-3312 (Pubitemid 38581437)
90. Lovat PE, Ranalli M, Corazzari M, et al. Mechanisms of free-radical induction in relation to fenretinide-induced apoptosis of neuroblastoma. J Cell Biochem 2003;89:698-708 (Pubitemid 36759131)
91. Engel RH, Evans AM. Oxidative stress and apoptosis: a new treatment paradigm in cancer. Front Biosci 2006;11:300-312 (Pubitemid 43253493)
92. Wu JM, DiePietrantonio AM, Hseih TC. Mechanism of fenretinide (4-HPR)-induced cell death. Apoptosis 2001;6:377-388 (Pubitemid 32910879)
93. Myatt S, Redfern C, Burchill S. p38 MAPK-Dependent Sensitivity of Ewing's Sarcoma Family of Tumors to Fenretinide-Induced Cell Death. Clin Cancer Res 2005;11(8):3136-3148 (Pubitemid 40525221)
94. Magwere T, Myatt SS, Burchill SA. Manipulation of oxidative stress to induce cell death in Ewing's sarcoma family of tumours. Eur J Cancer 2008, doi:10.1016/j.ejca.2008.06.008 [Last accessed 12 November 2008]
95. Garaventa A, Luksch R, Piccolo M, et al. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 2003;9:2032-2039 (Pubitemid 36687622)
96. Villablanca JG, Krailo MM, Ames AM, et al. Phase I trial of oral fenretinide in children with high-risk solid tumours: A report from the Children's Oncology Group (CCG 09709). J Clin Oncol 2006;24:3423-3430 (Pubitemid 46638899)
97. Smith MR. Antitumour activity of Bisphosphonates. Clin Cancer Res 2003;9:5433-5434
98. Sonneman J, Eckervogt V, Truckenbrod B, et al. The bisphosphonate pamidronate is a potent inhibitor of Ewing's sarcoma cell growth in vitro. Anticancer Drugs 2003;14:767-771 (Pubitemid 37357703)
99. Kubo T, Shimose S, Matsuo T, et al. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells. J Ortho Res 2006;24:1138-1144 (Pubitemid 43870875)
100. Kubo T, Shimose S, Matsuo T, et al. Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells. Cancer Chemother Pharmacol 2008;62:111-116 (Pubitemid 351537851)
101. Zhou Z, Guan H, Duan X, Klinerman E. Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Cancer 2005;104:1713-1720 (Pubitemid 41437436)
102. Ambros IM, Ambros PF, Strehl S, et al. MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer 1991;7(7):1886-1893
103. Kovar H, Dworzak M, Strehl S, et al. Overexpression of the pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral primitive neuroectodermal tumor. Oncogene 1990;5(7):1067-1070 (Pubitemid 20220252)
104. Cerisano V, Aalto Y, Perdichizzi S, et al. Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators. Oncogene 2004;23(33):5664 (Pubitemid 39093044)
105. Scotlandi K, Baldini N, Cerisano V, et al. CD99 engagement: an effective therapeutic strategy for Ewing tumors. Cancer Res 2000;60(18):5134-5142 (Pubitemid 30739771)
106. Scotlandi K, Perdichizzi S, Bernard G, et al. Targeting CD99 in association with doxorubicin: an effective combined treatment for Ewing's sarcoma. Eur J Cancer 2006;42(1):91-96 [Epub 2005 Dec 2] (Pubitemid 41814537)
107. Rousseau R, Brenner K. Vaccine Therapies for Pediatric Malignancies. Cancer J 2005;11:331-339 (Pubitemid 44698800)
108. Gou W, Guo Y, Tang S, et al. Dendritic Cell-Ewing's Sarcoma Cell Hybrids Enhance Antitumor Immunity. Clin Orthoped Rel Res 2008;466:2176-2183
109. Dagher R, Long LM, Read EJ, et al. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol 2002;38:158-164 (Pubitemid 34171069)
110. Mackall CL, Rhee EH, Read EJ, et al. A Pilot Study of Consolidative Immunotherapy in Patients with High-Risk Pediatric Sarcomas. Clin Cancer Res 2008;14(15):4850-4858
111. Schaefer K, Eisenacher M, Braun Y, et al. Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur J Cancer 2008;44(5):699-709 [Epub 2008 Feb 21]
112. Lustig B, Behrens J. The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol 2003;129(4):199-221 (Pubitemid 36713796)
113. Mikami I, You L, He B, et al. Efficacy of Wnt-1 monoclonal antibody in sarcoma cells. BMC Cancer 2005;5(1):53 (Pubitemid 41461077)
114. Rizzo P, Osipo C, Foreman K, et al. Rational targeting of Notch signaling in cancer. Oncogene 2008;27(38):5124-5131
115. Baliko F, Bright T, Poon R, et al. Inhibition of Notch Signaling Induces Neural differentiation in Ewing Sarcoma. Am J Pathol 2007;170(5):1686-1694 (Pubitemid 47339313)
116. Holzer G, Obermair A, Koschat M, et al. Concentration of Vascular Endothelial Growth Factor (VEGF) in the Serum of Patients with Malignant Bone Tumours. Med Pediatr Oncol 2001;36:601-604 (Pubitemid 32402155)
117. Fuchs B, Inwards CY, Janknecht R. Vascular Endothelial Growth Factor Expression is Up-Regulated by EWS-ETS Oncoproteins and Sp1 and May Represent an Independent Predictor of Survival in Ewing's Sarcoma. Clin Cancer Res 2004;10:1344-1353 (Pubitemid 38365227)
118. Zhou Z, Zhou RR, Guan H, et al. E1A gene therapy inhibits angiogenesis in a Ewing's sarcoma animal model. Mol Cancer Ther 2003;2(12):1313-1319
119. The European and American Osteosarcoma Study Group. Available from: http://www.ctu.mrc.ac.uk/euramos/ [Last accessed 12 November 2008]
120. Cheung I, Feng Y, Danis K, et al. Novel Markers of subclinical disease for Ewing Family Tumors from Gene Expression Profiling. Clin Cancer Res 2007;13(23):6978-6983 (Pubitemid 350276878)
121. Oeffinger K, Mertens A, Sklar C, et al. Chronic Health Conditions in Adult Survivors of Childhood Cancer. N Engl J Med 2006;355:1572-1582 •• Comprehensive study of the late effects of cancer chemotherapy. (Pubitemid 44547808)
122. Study of CP-751,871 In Patients With Ewing's Sarcoma Family of Tumors. Available from: http://www.cancer.gov/clinicaltrials/search [Last accessed 12 November 2008]
123. A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent. Available from: http://www.cancer.gov/clinicaltrials/search [Last accessed 12 November 2008]
124. A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors. Available from: http://www.cancer. gov/clinicaltrials/search [Last accessed 12 November 2008]
125. A Study to Determine the Activity of SCH 717454 in Subjects With Relapsed Osteosarcoma or Ewing's Sarcoma (Study P04720). Available from: http://www.cancer.gov/clinicaltrials/search [Last accessed 12 November 2008]
126. Phase 1 Study of Intermittent or Continuous OSI-906 Dosing. Available from: http://www.cancer.gov/clinicaltrials/search [Last accessed 12 November 2008]
127. A Pilot Study of Tumor Cell Vaccine for High-Risk Solid Tumor Patients Following Stem Cell Transplantation (UMCC 2005.050). Available from: http://www.cancer.gov/clinicaltrials/search [Last accessed 19 December 2008]
128. Vaccine Therapy in Treating Young Patients With Newly Diagnosed Metastatic or Recurrent Ewing Sarcoma Family of Tumors, Rhabdomyosarcoma, or Neuroblastoma (NCI-07-C-0206). Available from: http://www.cancer.gov/ clinicaltrials [Last accessed 19 December 2008]